CA2352194A1 - Azepinoindole derivatives, the production and use thereof - Google Patents

Azepinoindole derivatives, the production and use thereof Download PDF

Info

Publication number: CA2352194A1
Authority: CA; Canada
Prior art keywords: alkyl; formula; hydrogen; phenyl; treatment
Prior art date: 1999-09-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002352194A

Other languages

English (en)

French (fr)

Inventor

Wilfried Lubisch

Michael Kock

Thomas Hoger

Roland Grandel

Reinhold Muller

Sabine Schult

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott GmbH and Co KG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-28

Filing date

2000-09-15

Publication date

2001-04-05

1999-09-28 Priority claimed from DE19946289A external-priority patent/DE19946289A1/de

2000-08-09 Priority claimed from DE10039610A external-priority patent/DE10039610A1/de

2000-09-15 Application filed by Individual filed Critical Individual

2001-04-05 Publication of CA2352194A1 publication Critical patent/CA2352194A1/en

Status Abandoned legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 19
ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 title description 14
150000001875 compounds Chemical class 0.000 claims abstract description 44
239000001257 hydrogen Substances 0.000 claims description 34
229910052739 hydrogen Inorganic materials 0.000 claims description 34
238000011282 treatment Methods 0.000 claims description 30
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
125000004432 carbon atom Chemical group C* 0.000 claims description 22
150000002431 hydrogen Chemical class 0.000 claims description 22
229920006395 saturated elastomer Polymers 0.000 claims description 20
125000004434 sulfur atom Chemical group 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
229910052799 carbon Inorganic materials 0.000 claims description 14
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
239000000460 chlorine Substances 0.000 claims description 12
229910052801 chlorine Inorganic materials 0.000 claims description 12
230000006378 damage Effects 0.000 claims description 12
229910052731 fluorine Inorganic materials 0.000 claims description 12
239000011737 fluorine Substances 0.000 claims description 12
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
229910052794 bromium Inorganic materials 0.000 claims description 11
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 11
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
125000004430 oxygen atom Chemical group O* 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
150000001721 carbon Chemical group 0.000 claims description 6
208000028867 ischemia Diseases 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 5
210000003734 kidney Anatomy 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
150000001412 amines Chemical class 0.000 claims description 4
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 4
210000001367 artery Anatomy 0.000 claims description 4
230000001037 epileptic effect Effects 0.000 claims description 4
230000004770 neurodegeneration Effects 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
239000000651 prodrug Substances 0.000 claims description 4
229940002612 prodrug Drugs 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
-1 C1-C4-alkylphenyl Chemical group 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
206010040070 Septic Shock Diseases 0.000 claims description 3
230000009089 cytolysis Effects 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
230000036303 septic shock Effects 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
206010002329 Aneurysm Diseases 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
229930105110 Cyclosporin A Natural products 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
206010019196 Head injury Diseases 0.000 claims description 2
208000032843 Hemorrhage Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
208000034486 Multi-organ failure Diseases 0.000 claims description 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
206010034759 Petit mal epilepsy Diseases 0.000 claims description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
206010063897 Renal ischaemia Diseases 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
210000004351 coronary vessel Anatomy 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
229930182912 cyclosporin Natural products 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
210000003709 heart valve Anatomy 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
208000014674 injury Diseases 0.000 claims description 2
238000012961 medicinal therapy Methods 0.000 claims description 2
230000007576 microinfarct Effects 0.000 claims description 2
208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
208000010125 myocardial infarction Diseases 0.000 claims description 2
208000031225 myocardial ischemia Diseases 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
230000002093 peripheral effect Effects 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
238000002271 resection Methods 0.000 claims description 2
230000000250 revascularization Effects 0.000 claims description 2
210000003478 temporal lobe Anatomy 0.000 claims description 2
229930192474 thiophene Chemical group 0.000 claims description 2
230000008733 trauma Effects 0.000 claims description 2
101100134927 Gallus gallus COR8 gene Proteins 0.000 claims 2
230000003961 neuronal insult Effects 0.000 claims 2
229910052760 oxygen Inorganic materials 0.000 claims 2
229910052717 sulfur Inorganic materials 0.000 claims 2
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
229910006074 SO2NH2 Inorganic materials 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
230000002566 clonic effect Effects 0.000 claims 1
125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
125000000565 sulfonamide group Chemical group 0.000 claims 1
230000001256 tonic effect Effects 0.000 claims 1
JBXRLVPILRXPNH-UHFFFAOYSA-N indol-6-one Chemical compound O=C1C=CC2=CC=NC2=C1 JBXRLVPILRXPNH-UHFFFAOYSA-N 0.000 description 34
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 26
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 26
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 13
239000000243 solution Substances 0.000 description 8
239000003112 inhibitor Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000012661 PARP inhibitor Substances 0.000 description 5
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
239000011534 wash buffer Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
230000007574 infarction Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 2
208000009304 Acute Kidney Injury Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
230000005778 DNA damage Effects 0.000 description 2
231100000277 DNA damage Toxicity 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
238000000034 method Methods 0.000 description 2
229960003966 nicotinamide Drugs 0.000 description 2
235000005152 nicotinamide Nutrition 0.000 description 2
239000011570 nicotinamide Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
108091006091 regulatory enzymes Proteins 0.000 description 1
229960002917 reteplase Drugs 0.000 description 1
108010051412 reteplase Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003457 sulfones Chemical group 0.000 description 1
150000003462 sulfoxides Chemical group 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CA002352194A 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof Abandoned CA2352194A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE19946289.5		1999-09-28
DE19946289A DE19946289A1 (de)	1999-09-28	1999-09-28	Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610.0		2000-08-09
DE10039610A DE10039610A1 (de)	2000-08-09	2000-08-09	Azepinoindol-Derivate, deren Herstellung und Anwendung
PCT/EP2000/009024 WO2001023390A2 (de)	1999-09-28	2000-09-15	Azepinoindol-derivate, deren herstellung und anwendung

Publications (1)

Publication Number	Publication Date
CA2352194A1 true CA2352194A1 (en)	2001-04-05

Family

ID=26006691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002352194A Abandoned CA2352194A1 (en)	1999-09-28	2000-09-15	Azepinoindole derivatives, the production and use thereof

Country Status (17)

Country	Link
EP (1)	EP1183259A2 (sk)
JP (1)	JP2003510328A (sk)
KR (1)	KR20010087401A (sk)
CN (1)	CN1374961A (sk)
AU (1)	AU1271201A (sk)
BG (1)	BG105650A (sk)
BR (1)	BR0007174A (sk)
CA (1)	CA2352194A1 (sk)
CZ (1)	CZ20012373A3 (sk)
HK (1)	HK1048999A1 (sk)
HU (1)	HUP0104917A3 (sk)
IL (1)	IL143349A0 (sk)
NO (1)	NO20012567L (sk)
PL (1)	PL347885A1 (sk)
SK (1)	SK8842001A3 (sk)
TR (1)	TR200101499T1 (sk)
WO (1)	WO2001023390A2 (sk)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7662824B2 (en)	2005-03-18	2010-02-16	Janssen Pharmaceutica Nv	Acylhydrazones as kinase modulators
US7981890B2 (en)	2007-09-14	2011-07-19	Astrazeneca Ab	Phthalazinone derivatives
US8129380B2 (en)	2008-01-23	2012-03-06	Astrazeneca Ab	Phthalazinone derivatives
US8475842B2 (en)	2008-10-07	2013-07-02	Astrazeneca Ab	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS50031B (sr)	1999-01-11	2008-11-28	Agouron Pharmaceuticals Inc.,	Triciklični inhibitori poli(adp-riboza)polimeraza
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
WO2002044183A2 (en) *	2000-12-01	2002-06-06	Guilford Pharmaceuticals Inc.	Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
US7026311B2 (en)	2002-01-10	2006-04-11	Abbott Gmbh & Co., Kg	Dibenzodiazepine derivatives, their preparation and use
AU2003229953A1 (en)	2002-04-30	2003-11-17	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
ATE546539T1 (de)	2002-07-26	2012-03-15	Basf Plant Science Gmbh	Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
WO2005028467A1 (en)	2003-09-15	2005-03-31	Anadys Pharmaceuticals, Inc.	Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
ES2371469T3 (es)	2003-12-01	2012-01-03	Kudos Pharmaceuticals Limited	Inhibidores de reparación de daños en adn para el tratamiento del cáncer.
US7772271B2 (en)	2004-07-14	2010-08-10	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
CA2573185A1 (en)	2004-07-14	2006-02-23	Ptc Therapeutics, Inc.	Methods for treating hepatitis c
US7781478B2 (en)	2004-07-14	2010-08-24	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7868037B2 (en)	2004-07-14	2011-01-11	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7645881B2 (en)	2004-07-22	2010-01-12	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
AU2006222012B2 (en)	2005-03-08	2011-03-31	Basf Plant Science Gmbh	Expression enhancing intron sequences
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
GB0804755D0 (en) *	2008-03-14	2008-04-16	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2011058367A2 (en)	2009-11-13	2011-05-19	Astrazeneca Ab	Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2504429B1 (en)	2009-11-27	2016-04-20	BASF Plant Science Company GmbH	Chimeric endonucleases and uses thereof
CN102762726A (zh)	2009-11-27	2012-10-31	巴斯夫植物科学有限公司	嵌合内切核酸酶及其用途
BR112012012588B1 (pt)	2009-11-27	2019-03-26	Basf Plant Science Company Gmbh	Endonuclease, método para recombinação homóloga de polinucleotídeos e método para mutação direcionada de polinucleotídeos
SG186885A1 (en)	2010-06-04	2013-02-28	Albany Molecular Res Inc	Glycine transporter-1 inhibitors, methods of making them, and uses thereof
LT3325623T (lt)	2015-07-23	2019-10-25	Inst Curie	Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti
GB201519573D0 (en)	2015-11-05	2015-12-23	King S College London	Combination
WO2018162439A1 (en)	2017-03-08	2018-09-13	Onxeo	New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3615026B1 (en)	2017-04-28	2021-03-03	Akribes Biomedical GmbH	A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
EP3630287B1 (en) *	2017-05-24	2025-12-10	The Trustees Of The University Of Pennsylvania	Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
US20200407720A1 (en)	2018-03-13	2020-12-31	Onxeo	A dbait molecule against acquired resistance in the treatment of cancer
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
CN113365998B (zh) *	2019-02-02	2023-04-14	正大天晴药业集团股份有限公司	用于parp抑制剂的吲哚并七元酰肟类似物
CN114072410B (zh) *	2019-08-01	2023-08-01	正大天晴药业集团股份有限公司	作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en)	2019-09-10	2019-10-23	Francis Crick Institute Ltd	Treatment of hr deficient cancer
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US20230331739A1 (en) *	2020-07-31	2023-10-19	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same
WO2024261243A1 (en)	2023-06-21	2024-12-26	Hemispherian As	Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999011644A1 (en) *	1997-09-03	1999-03-11	Guilford Pharmaceuticals Inc.	Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
RS50031B (sr) *	1999-01-11	2008-11-28	Agouron Pharmaceuticals Inc.,	Triciklični inhibitori poli(adp-riboza)polimeraza
ECSP003637A (es) *	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas

2000
- 2000-09-15 HU HU0104917A patent/HUP0104917A3/hu unknown
- 2000-09-15 BR BR0007174-9A patent/BR0007174A/pt not_active IP Right Cessation
- 2000-09-15 PL PL00347885A patent/PL347885A1/xx not_active Application Discontinuation
- 2000-09-15 KR KR1020017006614A patent/KR20010087401A/ko not_active Ceased
- 2000-09-15 SK SK884-2001A patent/SK8842001A3/sk unknown
- 2000-09-15 CN CN00802408A patent/CN1374961A/zh active Pending
- 2000-09-15 IL IL14334900A patent/IL143349A0/xx unknown
- 2000-09-15 CZ CZ20012373A patent/CZ20012373A3/cs unknown
- 2000-09-15 EP EP00974379A patent/EP1183259A2/de not_active Withdrawn
- 2000-09-15 CA CA002352194A patent/CA2352194A1/en not_active Abandoned
- 2000-09-15 JP JP2001526542A patent/JP2003510328A/ja active Pending
- 2000-09-15 WO PCT/EP2000/009024 patent/WO2001023390A2/de not_active Ceased
- 2000-09-15 HK HK03101179.8A patent/HK1048999A1/zh unknown
- 2000-09-15 AU AU12712/01A patent/AU1271201A/en not_active Abandoned
- 2000-09-15 TR TR2001/01499T patent/TR200101499T1/xx unknown
2001
- 2001-05-25 NO NO20012567A patent/NO20012567L/no not_active Application Discontinuation
- 2001-06-26 BG BG105650A patent/BG105650A/xx unknown

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7662824B2 (en)	2005-03-18	2010-02-16	Janssen Pharmaceutica Nv	Acylhydrazones as kinase modulators
US7981890B2 (en)	2007-09-14	2011-07-19	Astrazeneca Ab	Phthalazinone derivatives
US8129380B2 (en)	2008-01-23	2012-03-06	Astrazeneca Ab	Phthalazinone derivatives
US8475842B2 (en)	2008-10-07	2013-07-02	Astrazeneca Ab	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US11633396B2 (en)	2008-10-07	2023-04-25	Kudos Pharmaceuticals Limited	Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one
US11975001B2 (en)	2008-10-07	2024-05-07	Kudos Pharmaceuticals Limited	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US12048695B2 (en)	2008-10-07	2024-07-30	Kudos Pharmaceuticals Limited	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US12144810B1 (en)	2008-10-07	2024-11-19	Kudos Pharmaceuticals Limited	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US12178816B2 (en)	2008-10-07	2024-12-31	Kudos Pharmaceuticals Limited	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one

Also Published As

Publication number	Publication date
PL347885A1 (en)	2002-04-22
BG105650A (en)	2002-02-28
NO20012567L (no)	2001-06-25
WO2001023390A2 (de)	2001-04-05
NO20012567D0 (no)	2001-05-25
JP2003510328A (ja)	2003-03-18
CZ20012373A3 (cs)	2002-05-15
WO2001023390A3 (de)	2001-12-27
KR20010087401A (ko)	2001-09-15
AU1271201A (en)	2001-04-30
CN1374961A (zh)	2002-10-16
SK8842001A3 (en)	2002-01-07
HK1048999A1 (zh)	2003-04-25
HUP0104917A2 (hu)	2002-04-29
TR200101499T1 (tr)	2002-09-23
HUP0104917A3 (en)	2002-12-28
EP1183259A2 (de)	2002-03-06
IL143349A0 (en)	2002-04-21
BR0007174A (pt)	2001-09-04

Publication	Publication Date	Title
CA2352194A1 (en)	2001-04-05	Azepinoindole derivatives, the production and use thereof
US7087637B2 (en)	2006-08-08	Substituted indoles which are PARP inhibitors
US7041675B2 (en)	2006-05-09	Heterocyclic compounds and their use as PARP inhibitors
US6509365B1 (en)	2003-01-21	2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
US6737421B1 (en)	2004-05-18	Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors
US6448271B1 (en)	2002-09-10	Substituted benzimidazoles and their use as parp inhibitors
ES2251405T3 (es)	2006-05-01	Derivados de benzodiazepina, su obtencion y aplicacion.
CA2472107C (en)	2008-10-28	Dibenzodiazepine derivates, their preparation and use
MXPA01005199A (en)	2002-06-05	Azepinoindole derivatives, the production and use thereof
MXPA01010673A (es)	2002-06-05	Benzimidazoles ciclo-alquil substituidos y su uso como inhibidores parp
MXPA01004869A (en)	2002-05-09	2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
MXPA01005197A (en)	2002-05-09	Substituted benzimidazoles and their use as parp inhibitors

Legal Events

Date	Code	Title	Description
2001-05-25	EEER	Examination request
2003-09-15	FZDE	Discontinued